Breaking the chronic cycle of inflammatory diseases.
Disease Focus
Chronic inflammatory diseases destroy lives every day. We are highly attuned to the serious comorbidities associated with chronic inflammatory diseases, and patients are often at risk for more than they may realize, with treatments that are often intended for little more than symptomatic relief of their symptoms.
Our focus is to seek solutions that go beyond symptomatic relief to halt disease progression and ultimately reduce mortality. That is the heart of the Evommune approach – to look beyond symptom control to address the underlying factors that drive pathology.
Our goal is to develop accessible innovations that not only address the symptoms of chronic inflammatory disease, but also halt disease progression and prevent medical complications in the future.
An additional target of current investigations is IL-18, a pro-inflammatory cytokine of the IL-1 family that drives innate and adaptive immune processes related to infection, inflammation, and autoimmunity. We are targeting IL-18 with a long-acting injectable therapeutic, EVO-301, an IL-18BP fusion-protein that is designed to neutralize the signal pathway of IL-18 for the regulation of inflammation.